Annex
United Kingdom
| The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance. | |||||
| Common Name | IUPAC NameIdentification Numbers | Minimum degree of purity of the active substancef1 | Expiry date of approval | Product type | Specific conditions |
|---|---|---|---|---|---|
| Warfarin | IUPAC Name: (RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl) coumarin EC No: 201-377-6 CAS No: 81-81-2 | 990 g/kg | 30 June 2024 | 14 | Warfarin is considered a candidate for substitution in accordance with points (a) and (e) of Article 10(1) of Regulation (EU) No 528/2012. The authorisations of biocidal products are subject to the following general conditions:
In addition to the general conditions, the authorisations of biocidal products to be used by the general public are subject to the following conditions:
In addition to the general conditions, the authorisations of biocidal products to be used by professionals are subject to the following conditions:
In addition to the general conditions, the authorisations of biocidal products to be used by trained professionals are subject to the following conditions:
|
Annotations
Footnotes
- f1
-
The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.